Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis

Lucheng Zhu,Saisai Jing,Bing Wang,Kan Wu,M. A. Shenglin,Shirong Zhang

DOI: https://doi.org/10.1007/s12253-015-0011-z

2015-01-01

Abstract:Anti-PD-1/PD-L1 antibodies showed satisfactory efficacy in treating non-small-cell lung cancer. We conducted this meta-analysis to explore the advantage subtypes and best therapeutic modalities of Anti-PD-1/PD-L1 therapy on NSCLC. A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and the Cochrane Library. The pooled ORR, 6-month progression-free survival rate (PFSR 6m ), and 1-year overall survival rate (OSR 1y ) were calculated and compared. 15 trials were included in this meta-analysis. Our analyses demonstrated the pooled ORR of 1st line and 2nd or more line anti-PD-1/PD-L1 therapy were 36.5 % (21.9–51.0 %) and 17.0 % (14.3–19.7 %), respectively. While the difference was significant (Z = 3.31, p < 0.001). The pooled ORR for non-squamous and squamous cell lung cancer were 18.5 % (16.0–21.1 %) and 17.9 % (14.4–21.5 %), respectively. The difference was not significant (Z = 0.27, p = 0.791). The pooled ORR for PD-L1 positive and negative patients were 29.6 % (21.6–37.6 %) and 13.5 % (10.6–16.3 %), respectively. The difference was significant (Z = 4.39, p < 0.001). The PFSR 6m for PD-L1 positive and negative NSCLC were 50.0 % (40.5–62.3 %) and 27.0 % (19.2–34.7 %). The difference was significant (Z = 3.72, p < 0.001). The OSR 1y for PD-L1 positive and negative NSCLC were 66.8 % (44.8 %-88.9 %) and 54.0 % (32.6–75.3 %). The difference was not significant (Z = 0.77, p = 0.441). Anti-PD-1/PD-L1 antibody can serve as a promising treatment option for NSCLC. Patients with positive PD-L1 expression may benefit more from anti-PD-1/PD-L1 therapy. 1st-line anti-PD-1/PD-L1 therapy can be chosen as the best modality. Squamous cell lung cancer also benefit from anti-PD-1/PD-L1 therapy.